Targeted Therapies in Oncology
January 2021
Volume: 10
Issue: 1
December 2, 2020
Volume: 9
Issue: 18
December 1 2020
Volume: 9
Issue: 17
November 2 2020
Volume: 9
Issue: 16
November 1 2020
Volume: 9
Issue: 15
October 2 2020
Volume: 9
Issue: 14
October 1, 2020
Volume: 9
Issue: 13
September 1 2020
Volume: 9
August 1 2020
Volume: 9
Issue: 1
July 1 2020
Volume: 9
Issue: 9
July 2 2020
Volume: 9
Issue: 10
June 1 2020
Volume: 9
Issue: 8
May 1 2020
Volume: 9
Issue: 5
April 2 2020
Volume: 9
Issue: 6
April 1 2020
Volume: 9
Issue: 5
March 1 2020
Volume: 9
Issue: 4
February 2 2020
Volume: 9
Issue: 3
February 1 2020
Volume: 9
Issue: 2
January 2020
Volume: 9
Issue: 1
December 2
Volume: 8
Issue: 18
December 1
Volume: 8
Issue: 17
November 2 2019
Volume: 8
Issue: 16
November 1 2019
Volume: 8
Issue: 15
October 2 2019
Volume: 8
Issue: 14
October 2019
Volume: 8
Issue: 13
September 2019
Volume: 8
Issue: 12
August 2019
Volume: 8
Issue: 11
July 2019
Volume: 8
Issue: 9
July 2
Volume: 8
Issue: 10
June 2019
Volume: 8
Issue: 8
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5